Earnings Momentum: Absci's latest quarterly results highlighted advancing clinical trials for its lead candidate ABS-201 in androgenetic alopecia, with initial safety data proving favorable and multiple cohorts dosed successfully. Social media buzz focused on the company's shift toward clinical-stage development, though some noted rising R&D costs and a cash runway extending into mid-2028. Investors expressed measured excitement amid the stock's high implied volatility post-earnings.
Trial Anticipation: Discussion centered on upcoming proof-of-concept readouts for ABS-201 expected in the second half of 2026, alongside plans for endometriosis studies. Users pointed to positive pharmacokinetic data supporting the dosing regimen, yet flagged management caveats on hair growth efficacy and historical challenges in similar therapies. The narrative underscored Absci's AI-driven platform as a potential differentiator in biotech.
AI Biotech Surge: Broader chatter positioned Absci within an emerging wave of AI-enabled biotechs, with predictions of significant progress in the coming year. Portfolio builders included the stock in high-risk, high-reward AI-pharma bets, tempered by concerns over trial read-throughs and cash management. Sentiment reflected growing optimism for clinical catalysts despite lingering execution risks.
Note: This discussion summary was generated from an AI condensation of post data.
Absci Insider Trading Activity
Absci insiders have traded $ABSI stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABSI stock by insiders over the last 6 months:
- ANDREAS BUSCH (Chief Innovation Officer) purchased 100,000 shares for an estimated $229,000
- HOUTEN FRANS VAN purchased 40,000 shares for an estimated $148,800
- SEAN MCCLAIN (Chief Executive Officer) sold 26,761 shares for an estimated $80,015
- ZACHARIAH JONASSON (CFO / CBO) sold 17,496 shares for an estimated $52,313
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Absci Hedge Fund Activity
We have seen 68 institutional investors add shares of Absci stock to their portfolio, and 55 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 3,925,926 shares (+190.1%) to their portfolio in Q4 2025, for an estimated $13,701,481
- SCHONFELD STRATEGIC ADVISORS LLC added 2,349,725 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,200,540
- BAKER BROS. ADVISORS LP added 2,134,803 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,450,462
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,085,501 shares (+2955.4%) to their portfolio in Q4 2025, for an estimated $7,278,398
- CITADEL ADVISORS LLC added 1,778,545 shares (+1077.3%) to their portfolio in Q4 2025, for an estimated $6,207,122
- PARKMAN HEALTHCARE PARTNERS LLC added 1,458,652 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,090,695
- TWO SIGMA INVESTMENTS, LP added 1,291,261 shares (+1015.5%) to their portfolio in Q4 2025, for an estimated $4,506,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Absci Analyst Ratings
Wall Street analysts have issued reports on $ABSI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/18/2025
- Needham issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for Absci, check out Quiver Quantitative's $ABSI forecast page.
Absci Price Targets
Multiple analysts have issued price targets for $ABSI recently. We have seen 2 analysts offer price targets for $ABSI in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Gil Blum from Needham set a target price of $7.0 on 03/30/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $8.0 on 12/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
